RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New triple therapy aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC